Raybow Pharma is headquartered in a pharmaceutical production zone in Linhai, Taizhou city of Zhejiang Province. Construction started in 2008, and the facility now covers an area of about 120,000 square meters with 1500+ employees. In 2019 a 10,000 square meter PR&D lab was opened in Hangzhou, China. Raybow acquired a lab and manufacturing site in Brevard, NC in the United States and a modern manufacturing site in Suzhou, China. In March of 2020 Raybow added a modern 10,000 square meter PR&D lab to its Linhai site. The company has passed official GMP audits from the USFDA, CFDA and EMEA member countries in recent years. Raybow Pharma has applied the concept of green chemical production and manufacturing. Both the Suzhou and Linhai sites have advanced environmental protection & treatment systems, featuring solutions for the company's waste treatment, and technology for implementing green production and recirculation. Our R&D team has resourceful multi-field experienced and international personnel, over 300 people in total, who provide our customers with complete solutions for CDMO projects. Raybow Pharma’s team is committed to the research and development of new pharmaceutical technology, especially in the area of flow chemistry, high-end fluorine chemistry, asymmetric chiral synthesis, glycosides and biological enzyme technology.

Sales Markets

North America (USA, Canada); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries)

Meet us at

CPhI Worldwide 2021

Fiera Milano, Milan, Italy

9-11 November 2021

Book a meeting
View Our Exhibitor Profile

Contact information




View All Contact Info